StockData
Monopar Therapeutics logo

Monopar Therapeutics (MNPR) stock

MNPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$71.06−0.91 (-1.26%)

Close on Nov 17, 2026Market cap $476.97MP/E –Yield –

Monopar Therapeutics cash

Cash and short-term investments held at the end of each period.

Monopar Therapeutics's cash was $105.37M at Jun 30, 2026. For fiscal 2025 it was $122.71M, up 34.3% from the year before. Over ten years it grew 45.9% a year on average. The highest annual figure on record is $122.71M in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$122.71M+34.3%
FY2024Dec 31, 2024$91.35M+561.4%
FY2023Dec 31, 2023$13.81M+13.4%
FY2022Dec 31, 2022$12.18M-39.1%
FY2021Dec 31, 2021$20.01M+19.6%
FY2020Dec 31, 2020$16.74M+26.7%
FY2019Dec 31, 2019$13.21M+91.7%
FY2018Dec 31, 2018$6.89M-29.5%
FY2017Dec 31, 2017$9.78M+240.5%
FY2016Dec 31, 2016$2.87M+2.4%
FY2015Dec 31, 2015$2.81M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$105.37M+33.7%
Q1 FY2026Mar 31, 2026$104.91M+32.4%
Q4 FY2025Dec 31, 2025$122.71M+34.3%
Q3 FY2025Sep 30, 2025$255.17M+2059.6%
Q2 FY2025Jun 30, 2025$78.83M+506.5%
Q1 FY2025Mar 31, 2025$79.23M+394.4%
Q4 FY2024Dec 31, 2024$91.35M+561.4%
Q3 FY2024Sep 30, 2024$11.82M-10.3%
Q2 FY2024Jun 30, 2024$13.00M-20.4%
Q1 FY2024Mar 31, 2024$16.03M+53.8%
Q4 FY2023Dec 31, 2023$13.81M+13.4%
Q3 FY2023Sep 30, 2023$13.17M-8.0%
Q2 FY2023Jun 30, 2023$16.33M-0.8%
Q1 FY2023Mar 31, 2023$10.42M-41.5%
Q4 FY2022Dec 31, 2022$12.18M-39.1%
Q3 FY2022Sep 30, 2022$14.32M-35.9%
Q2 FY2022Jun 30, 2022$16.46M-32.2%
Q1 FY2022Mar 31, 2022$17.82M-30.7%
Q4 FY2021Dec 31, 2021$20.01M+19.6%
Q3 FY2021Sep 30, 2021$22.34M+24.2%
Q2 FY2021Jun 30, 2021$24.29M+93.6%
Q1 FY2021Mar 31, 2021$25.72M+104.3%
Q4 FY2020Dec 31, 2020$16.74M+26.7%
Q3 FY2020Sep 30, 2020$17.98M+300.1%
Q2 FY2020Jun 30, 2020$12.55M+144.6%
Q1 FY2020Mar 31, 2020$12.59M+114.1%
Q4 FY2019Dec 31, 2019$13.21M+91.7%
Q3 FY2019Sep 30, 2019$4.49M-41.0%
Q2 FY2019Jun 30, 2019$5.13M-37.6%
Q1 FY2019Mar 31, 2019$5.88M-34.5%
Q4 FY2018Dec 31, 2018$6.89M-29.5%
Q3 FY2018Sep 30, 2018$7.62M-28.0%
Q2 FY2018Jun 30, 2018$8.22M+92.0%
Q1 FY2018Mar 31, 2018$8.97M+152.7%
Q4 FY2017Dec 31, 2017$9.78M+240.5%
Q3 FY2017Sep 30, 2017$10.59M+277.4%
Q2 FY2017Jun 30, 2017$4.28M–
Q1 FY2017Mar 31, 2017$3.55M–
Q4 FY2016Dec 31, 2016$2.87M–
Q4 FY2015Dec 31, 2015$2.81M–

More Monopar Therapeutics figures

See a number that looks wrong?